Yi Yang Xiangliang Liu Wei Song Jin Lu Na Yin Xiaojun Ye Xiao Chen
10.3389/fimmu.2022.907705
Front Immunol
2022 Jul 11;13:907705.
chemotherapy esophageal cancer hypopharyngeal squamous cell carcinoma immunotherapy sustained survival benefit
CC BY
https://pubmed.ncbi.nlm.nih.gov/35898511/
Carcinoma, Squamous Cell / pathology Esophageal Neoplasms / therapy Esophageal Squamous Cell Carcinoma / therapy Head and Neck Neoplasms Hypopharyngeal Neoplasms / pathology Hypopharyngeal Neoplasms / radiotherapy
Carcinoma, Squamous Cell / pathology Esophageal Neoplasms / therapy Esophageal Squamous Cell Carcinoma / therapy Head and Neck Neoplasms Hypopharyngeal Neoplasms / pathology Hypopharyngeal Neoplasms / radiotherapy Case Reports Humans Immunotherapy Retrospective Studies Squamous Cell Carcinoma of Head and Neck
PMC9311332
35898511
Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit
2022